Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 15/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987407 | 0.85 | HSD17B10 (0.56) | KDM4EALDH1A1HPGDSIGMAR1DRD3 | |
| SCHEMBL9109340 | 0.84 | SIGMAR1 (0.50) | SIGMAR1DRD3DRD2DRD4 | |
| SCHEMBL13345820 | 0.83 | KDM4E (0.50) | KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL9091761 | 0.82 | MEN1 (0.50) | KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL244414 | 0.82 | KDM4E (0.45) | KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL3741758 | 0.82 | KDM4E (0.60) | KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL16937088 | 0.81 | SOS1 (0.48) | KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL1710126 | 0.81 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL8966782 | 0.81 | KDM4E (0.59) | KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL18566637 | 0.80 | KDM4E (0.42) | KDM4EALDH1A1HPGDNPSR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2575454-B1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-8883850-B2 | Naphthalene carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883850-B2 | Naphthalene carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883850-B2 | Naphthalene carboxamide M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | disclosed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | disclosed |
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-8541380-B2 | C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same | GREEN CROSS CORPORATION (KR) | 2013-09-24 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
| WO-2011159067-A2 | THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159067-A2 | THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011149801-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149801-A1 | NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010147430-A2 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147430-A2 | NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2010-12-23 | — | — | WO | disclosed |
| US-5498628-A | ANTIPSYCHOTIC, PSYCHOSTIMULATORY, ANTIAUTISTIC, ANTIDEPRESSANT AND HYPOTENSIVE AGENTS, PARKINSON'S DISEASE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-03-12 | — | — | US | disclosed |
| EP-0585116-B1 | 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor | LILLY INDUSTRIES LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5389684-A | Treats disorder of central nervous system | LILLY INDUSTRIES LIMITED (GB) | 1995-02-14 | — | — | US | disclosed |
| EP-0585116-A1 | 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor | LILLY INDUSTRIES LIMITED (GB) | 1994-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, SLC10A2 | KDM4E 2710/4885ALDH1A1 1292/4885HPGD 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.